NENarges Eslami

Narges Eslami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Narges Eslami has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review

    by Meygol Mirzaei Rezaei, Mahdi Khosravi Nia, Kasra Allaei Rouzbahani, Maryam Kazemi, Negar Asghari Hosori, Mehdi Norouzi, Farzaneh Sotoudegan, Narges Eslami, Negar Ariamand, Vahid Shahnavaz, et al.

    Background and Aim: Human T‐Lymphotropic virus type 1 (HTLV‐1) infection can lead to HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating chronic neurological disease characterized by progressive lower limb spasticity and autonomic dysfunction. Because the exact disease pathogenesis remains unclear and current management options have limited efficacy, there is a critical need for more effective therapies to reduce morbidity and mortality. This narrative review aims to review the available and diverse range of emerging treatment approaches for HAM/TSP. Methods: A comprehensive narrative review of the existing literature was conducted to assess current treatment methods, historical treatment efforts, and modern therapeutic interventions. The scope includes pharmacological, immunological, targeted, and non‐pharmacological strategies aimed at disease management. Results: Current disease‐modifying therapies primarily rely on immunomodulatory agents, such as corticosteroids and interferon‐alpha, to mitigate neuroinflammation and preserve motor function, whereas traditional antiretroviral therapies demonstrate limited clinical efficacy. Emerging targeted therapies, notably the monoclonal antibody mogamulizumab, show significant promise in reducing HTLV‐1‐infected cells and sustaining a decrease in spinal cord inflammation. Furthermore, comprehensive care must integrate treatments targeting specific cellular signaling pathways alongside vital non‐pharmacological interventions, such as physical rehabilitation and psychological support. Conclusion: The effective management of HAM/TSP necessitates a holistic, multidisciplinary approach encompassing targeted pharmacotherapy, symptomatic management, and psychosocial support. While novel interventions and disease‐modifying therapies offer promising new directions, further high‐quality, randomized clinical trials are essential to establish standard regimens, optimize dosages, and ensure long‐term efficacy and safety.

  • Open Access

    Molecular epidemiology and genotype distribution of human papillomavirus in Iran: A nationwide retrospective study of over 100,000 referred individuals

    by Amir Aboofazeli, Zahra Sadeghi, Sheida Sarrafzadeh, Narges Eslami, Parsa Ghafari, Erfan Kordi, Ali Ahangar Kani, Arash Letafati, Fariba Yarandi, Vahdat Poortahmasebi, et al.

    Background and aim: Human papillomavirus (HPV) infection is a major public health challenge worldwide, especially in developing countries. This study assessed the nationwide molecular epidemiology and HPV genotype distribution in Iran to optimize public screening and Further strategies for vaccination in the country. Materials and methods: We conducted a nationwide multicenter retrospective observational study using HPV genotyping records obtained from participating laboratories across Iran between 2015 and 2024. Prevalence estimates, genotype distributions, and temporal trends were evaluated. Data were assessed for age, sex, and time trends using descriptive statistics and generalized linear models and were analyzed using R software. Results: The overall HPV prevalence in this group was 34.7%, with 56.7% of positive cases having at least one high-risk (HR) genotype. Men showed a significantly higher overall prevalence compared to women (44.4% vs. 34.1%, p < 0.001), although women had a higher proportion of HR-HPV among positive cases (59.2% vs. 35.6%). Over time, the overall HPV positivity rate increased by 7% per year from 2015 to 2024, whereas the proportion of HR-HPV among infected individuals decreased by 23% per year, reflecting an increase in low-risk strains such as HPV-6. Although HPV-16 was the predominant HR genotype (26.5% of HR cases), 77.7% of all HR-positive individuals carried non-16/18 carcinogenic strains of HPV. Conclusion: The epidemiological profile of HPV in Iran is evolving, characterized by an increase in overall prevalence and a predominant presence of non-16/18 HR genotypes. The significant burden of diverse carcinogenic strains highlights the limitations of exclusive bivalent or quadrivalent vaccination and standard 16/18-axis screening. The implementation of gender-neutral 9-valent vaccination programs with an emphasis on men and the expansion of routine diagnostic coverage to multiple molecular platforms are recommended as critical requirements for effective cancer prevention in Iran.

  • Open Access

    Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK‐Based Therapy

    by Farahnaz Joukar, Sara Yeganeh, Narges Eslami, Fariborz Mansour‐Ghanaei

    Background: Hepatitis C virus (HCV) infection is one of the leading causes of liver‐related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV infection among family members of HCV‐positive index cases, within related risk factors in them. Additionally, the study evaluated the therapeutic efficacy of the combination drug Sovodak (sofosbuvir–daclatasvir) based on HCV genotype. Methods: This study is a descriptive cross‐sectional study conducted on the families of individuals with Hepatitis C (12 people) within the Guilan cohort population. Twenty family members of HCV‐positive individuals were enrolled. Data were collected using structured questionnaires that included socio‐demographic and clinical information. Blood samples were drawn from each participant, and sera were separated for serological analysis. HCV antibody‐positive samples were assessed by HCV‐RNA detection. Subsequently, positive samples underwent HCV genotyping. Then, HCV‐positive individuals were referred in Phase 3 clinical trial with ID: NCT03200184. for treatment and follow‐up. Treatment consisted of Sovodak (a combination of sofosbuvir 400 mg and daclatasvir 60 mg). The clinical and diagnostic effectiveness of the treatment was evaluated 12 weeks after therapy initiation. Results: Out of the total cases, two were HCV antibody positive, and one of them was a 13‐year‐old girl who tested positive for HCV RNA by PCR. Her genotype was 1a, which matched her mother's genotype. This patient was successfully treated with Sovodak. The post‐treatment HCV RNA results were negative, indicating a sustained virologic response (SVR = 12). Conclusion: Evidence of intrafamilial transmission was observed in this study, its frequency was extremely low and statistically negligible. Shared household items, although seemingly unlikely, such as toothpaste, may serve as a potential route of transmission within families, independent of direct interpersonal contact.

  • Open Access

    Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations

    by Fatemeh Beygnejad, Narges Eslami, Kaveh Gharaei Nejad, Atefeh Zamani Kermanshahi, Hossein Bannazadeh Baghi

    Human papillomavirus (HPV), a non‐enveloped, double‐strand DNA viral pathogen, is intricately linked with the onset of various cancers, including cervical cancer and head and neck cancers. The present paper delves into HPV's ancient recognition and significant milestones such as the discovery of its role in oncogenesis and the development of preventive vaccines all the way to routine treatments and newer, cutting‐edge interventions. It highlights therapeutic advancements, including immunotherapies, gene‐editing technologies, and emerging vaccination strategies as well as the personalized HPV‐treatments plans to treat established infections. Challenges, such as vaccine accessibility, therapeutic resistance, and immune evasion, are examined, trying to capture the stigma around HPV and the social complications relating to the disease. The review concludes with future directions emphasizing innovation, equity in treatment access, and the integration of novel therapies to eradicate HPV‐associated diseases and highlight the necessity of Global eradication going forward. This paper aims to traverse the historical origins, molecular pathways, and clinical interventions aimed at understanding and managing HPV.


  • Dendritic Cell Therapy in Chronic Viral Infections: Current Applications, Challenges, and Future Perspectives

    by Mirsaeed Abdollahi, Reyhaneh Rasizadeh, Narges Eslami, Amir Hossein Ghafouri‐Asbagh, Vadood Noroozi, Somayeh Shokri, Hossein Bannazadeh Baghi

    Dendritic cells (DCs) are multifunctional cells that wield considerable influence in the shaping and modulation of the immune system. In immunotherapy, DC therapy has emerged as a dynamic and versatile approach with significant potential for combating viral infections. As elucidated through the exploration of HIV, and viral hepatitis, the trajectory of DC therapy is marked by tangible progress and transformative potential. Insights gained from ongoing studies can lead to the design of more effective vaccines that harness the power of dendritic cells, potentially providing long‐lasting immunity against viral infections. However, optimizing DC therapy presents several challenges that require dedicated efforts. This review focuses on the potential of DC‐based vaccines as a treatment for chronic viral infections like HIV, HBV, and HCV, where the virus remains in the body and causes long‐lasting problems with the immune system.

  • Open Access

    Occult Hepatitis B Infection among Hemodialysis Patients in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region

    by Narges Eslami, Vahdat Poortahmasebi, Javid Sadeghi, Reza Ghotaslou, Bahram Niknafs, Hossein Bannazadeh Baghi, Mahin Ahangar Oskouee

    Regardless of the extensive screening for the detection of hepatitis B surface antigen (HBsAg), hemodialysis (HD) patients are still severely at the risk of occult hepatitis B virus infection (OBI), especially in developing countries. OBI is defined as the presence of HBV DNA with undetectable HBsAg in the liver and/or Serum. This study aims to determine the prevalence of OBI in HD patients in East Azerbaijan Province, northwest of Iran, and inquire about the mutations in the detected HBsAg. In this cross-sectional descriptive study, ELISA method assessed serum and plasma samples of 118 HBsAg-negative patients undergoing HD treatment for HBV serological markers (HBsAg and Anti-HBc). Specific primers by nested polymerase chain reaction have been utilized to examine HBV DNA; also, direct sequencing of surface genes was carried out to characterize the viral genotypes and S gene mutations. Finally, followed by real-time PCR, the quantity of viral load in OBI-positive patients was determined. A total of 118 HD patients were included (63.6% were male and 36.4% female), with an overall mean age of 60.8 ± 12.8 years old. The prevalence of antihepatitis B core antibody (Anti-HBc) in the study population was 26.3% (31/118). Five patients (4.2%) were positive for HBV DNA and labeled OBI-positive; their plasma HBV-DNA load was less than 100 IU/ml. Following the phylogenetic analysis, the samples with OBI roughly belonged to genotype D, subtype ayw2 and only two had mutations within the S ’gene’s major hydrophilic region (MHR), including T123I, C124F, and P127T. This study reports the prevalence of OBI in the HBsAg-negative HD patients being at a rate of 4.2%, which can be a clinically vital consideration in this region. HBV serologic screening approaches need to be renewed to cover nucleic acid testing in the setting of hemodialysis and all the other high-risk groups associated with it (i.e., blood and organ donors).


  • Open Access

    SARS-CoV-2: Receptor and Co-receptor Tropism Probability

    by Narges Eslami, Parisa Shiri Aghbash, Ali Shamekh, Taher Entezari-Maleki, Javid Sadri Nahand, Abolfazl Jafari Sales, Hossein Bannazadeh Baghi

    The recent pandemic which arose from China, is caused by a pathogenic virus named “severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2)”. Its rapid global expansion has inflicted an extreme public health concern. The attachment of receptor-binding domains (RBD) of the spike proteins (S) to the host cell’s membrane, with or without the help of other cellular components such as proteases and especially co-receptors, is required for the first stage of its pathogenesis. In addition to humans, angiotensin-converting enzyme 2 (ACE2) is found on a wide range of vertebrate host’s cellular surface. SARS-CoV-2 has a broad spectrum of tropism; thus, it can infect a vast range of tissues, organs, and hosts; even though the surface amino acids of the spike protein conflict in the receptor-binding region. Due to the heterogeneous ACE2 distribution and the presence of different domains on the SARS-CoV-2 spike protein for binding, the virus entry into diverse host cell types may depend on the host cells’ receptor presentation with or without co-receptors. This review investigates multiple current types of receptor and co-receptor tropisms, with other molecular factors alongside their respective mechanisms, which facilitate the binding and entry of SARS-CoV-2 into the cells, extending the severity of the coronavirus disease 2019 (COVID-19). Understanding the pathogenesis of COVID-19 from this perspective can effectively help prevent this disease and provide more potent treatment strategies, particularly in vulnerable people with various cellular-level susceptibilities.


  • Viral coinfections in COVID‐19

    by Parisa Shiri Aghbash, Narges Eslami, Milad Shirvaliloo, Hossein Bannazadeh Baghi

    The most consequential challenge raised by coinfection is perhaps the inappropriate generation of recombinant viruses through the exchange of genetic material among different strains. These genetically similar viruses can interfere with the replication process of each other and even compete for the metabolites required for the maintenance of the replication cycle. Due to the similarity in clinical symptoms of most viral respiratory tract infections, and their coincidence with COVID‐19, caused by SARS‐CoV‐2, it is recommended to develop a comprehensive diagnostic panel for detection of respiratory and nonrespiratory viruses through the evaluation of patient samples. Given the resulting changes in blood markers, such as coagulation factors and white blood cell count following virus infection, these markers can be of diagnostic value in the detection of mixed infection in individuals already diagnosed with a certain viral illness. In this review, we seek to investigate the coinfection of SARS‐CoV‐2 with other respiratory and nonrespiratory viruses to provide novel insights into the development of highly sensitive diagnostics and effective treatment modalities.